Bicara Therapeutics Inc’s recent filing unveils that its Chief Legal Officer Meisner Lara unloaded Company’s shares for reported $1.02 million on Mar 14 ’25. In the deal valued at $12.90 per share,79,146 shares were sold. As a result of this transaction, Meisner Lara now holds 0 shares worth roughly $0.0.
Then, LARA S. MEISNER bought 79,146 shares, generating $1,056,599 in total proceeds.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 1,833,000 shares. Bicara Therapeutics Inc shares valued at $32,994,000 were divested by the Director at a price of $18.00 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 4,303,418 shares, worth roughly $54.48 million.
Wedbush initiated its Bicara Therapeutics Inc [BCAX] rating to an Outperform in a research note published on February 06, 2025; the price target was $31. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Rodman & Renshaw began covering BCAX with “Buy” recommendation on November 05, 2024. TD Cowen started covering the stock on October 08, 2024. It rated BCAX as “a Buy”.
Price Performance Review of BCAX
On Tuesday, Bicara Therapeutics Inc [NASDAQ:BCAX] saw its stock fall -2.84% to $12.66. Over the last five days, the stock has lost -2.84%. Bicara Therapeutics Inc shares have fallen nearly -27.32% since the year began.
Levels Of Support And Resistance For BCAX Stock
The 24-hour chart illustrates a support level at 12.26, which if violated will result in even more drops to 11.87. On the upside, there is a resistance level at 13.01. A further resistance level may holdings at 13.37. The Relative Strength Index (RSI) on the 14-day chart is 44.96, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.03, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.58%. Stochastics %K at 34.92% indicates the stock is a holding.
How much short interest is there in Bicara Therapeutics Inc?
A steep rise in short interest was recorded in Bicara Therapeutics Inc stocks on 2025-03-14, growing by 0.88 million shares to a total of 5.05 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.17 million shares. There was a rise of 17.41%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 08, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $47 price target.
